Trial of Taselisib in Overgrowth

Condition:   PIK3CA-Related Overgrowth Interventions:   Drug: Taselisib (GDC0032);   Drug: Taselisib (GDC0032) Sponsor:   Centre Hospitalier Universitaire Dijon Recruiting - verified September 2017

Source: ClinicalTrials.gov - September 19, 2017 Category: Research Source Type: clinical trials